Related Experiment Video

Updated: Nov 25, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

630

Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple

Carolin Schwake1, Ralf Gold1

  • 1Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791 Bochum, Germany.

Neurological Research and Practice
|December 16, 2020
PubMed

Insights

Long-term B-cell depletion therapy for multiple sclerosis (MS) may increase the risk of severe infections. This case highlights the need for vigilance regarding potential serious infections, such as pneumonia, in MS patients undergoing B-cell depletion treatments.

Area of Science:

  • Immunology
  • Neurology
  • Infectious Diseases

Background:

  • B-cell depletion using anti-CD20 antibodies is a standard treatment for multiple sclerosis (MS).
  • The long-term infection risks associated with B-cell depletion in MS patients are not fully understood.

Purpose of the Study:

  • To present a case of severe pneumonia in an MS patient following long-term B-cell depletion.
  • To emphasize the importance of recognizing infection risks in MS patients undergoing continuous B-cell depletion therapy.

Main Methods:

  • Case report of a 45-year-old male with relapsing-remitting MS treated with rituximab for 6 years.
  • Diagnostic workup included bronchoscopy and sputum testing to rule out tuberculosis.
  • Treatment involved prolonged antibiotic therapy.

Main Results:

  • The patient developed severe pneumonia with an unusual pulmonary cavity formation.
  • Tuberculosis was ruled out despite initial suspicion.
  • Complete recovery was achieved with broad-spectrum antibiotics.

Conclusions:

  • Continuous B-cell depletion in MS patients carries a risk of serious infections like severe pneumonia.
  • Vigilance and prompt diagnosis are crucial for managing infections in this patient population.
Keywords:
Multiple sclerosisPneumoniaPulmonary cavityRituximab

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.6K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.4K

Related Concept Videos

Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
627
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
596
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
549
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
956
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
633
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
218